Start-up
DeuterOncology NV
About DeuterOncology
DeuterOncology NV was founded in September 2020 by Dr Timothy Perera and is based in Liege in Belgium.
The company generated pre-clinical validation of DO-2, a novel, highly selective, brain penetrant deuterated MET kinase and RAS pathway inhibitor. Timothy Perera was the originator of the initial idea for the use of deuteration as a means to modulate metabolic properties of the parent drug and remains a strong champion of this exciting new molecule.
Facts about DeuterOncology
Facts about DeuterOncology
- Founding: 2020
- Focus : Service
- Industry : Biotechnology, Pharma
